Absence of germline mono-allelic promoter hypermethylation of the CDH1 gene in gastric cancer patients by Yamada, Hidetaka et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Molecular Cancer
Open Access Research
Absence of germline mono-allelic promoter hypermethylation of 
the CDH1 gene in gastric cancer patients
Hidetaka Yamada1, Kazuya Shinmura1, Masanori Goto1, Moriya Iwaizumi1, 
Hiroyuki Konno2, Hideki Kataoka3, Masami Yamada3, Takachika Ozawa4, 
Toshihiro Tsuneyoshi5, Fumihiko Tanioka6 and Haruhiko Sugimura*1
Address: 1First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan, 2Second Department of Surgery, 
Hamamatsu University School of Medicine, Hamamatsu, Japan, 3Department of Gastroenterology, Hamamatsu Medical Center, Hamamatsu, 
Japan, 4Department of Pathology, Hamamatsu Medical Center, Hamamatsu, Japan, 5Department of Materials and Life Science, Shizuoka Institute 
of Science and Technology, Fukuroi, Japan and 6Department of Pathology and Laboratory Medicine, Iwata City Hospital, Iwata, Japan
Email: Hidetaka Yamada - h-yamada@akiha.hama-med.ac.jp; Kazuya Shinmura - kzshinmu@hama-med.ac.jp; Masanori Goto - goto-m@hama-
med.ac.jp; Moriya Iwaizumi - iwaizumi@hama-med.ac.jp; Hiroyuki Konno - kon_6416@hama-med.ac.jp; Hideki Kataoka - kata-
hide@mail.dbs.ne.jp; Masami Yamada - masami.yamada@hmedc.or.jp; Takachika Ozawa - t.ozawa@hmedc.or.jp; 
Toshihiro Tsuneyoshi - tuneyosi@ms.sist.ac.jp; Fumihiko Tanioka - kyon8@juno.ocn.ne.jp; Haruhiko Sugimura* - hsugimur@hama-med.ac.jp
* Corresponding author    
Abstract
Background: Germline mono-allelic promoter hypermethylation of the MLH1 or MSH2 gene in
families with hereditary nonpolyposis colorectal cancer has recently been reported. The purpose
of this study was to evaluate if germline promoter hypermethylation of the tumor suppressor gene
CDH1 (E-cadherin) might cause predisposition to gastric cancer.
Methods: We prepared two groups of samples, a group of blood samples from 22 patients with
familial gastric cancer or early-onset gastric cancer selected from among 39 patients, and a group
of non-cancerous gastric tissue samples from 18 patients with sporadic gastric cancer showing loss
of CDH1 expression selected from among 159 patients. We then investigated the allele-specific
methylation status of the CDH1 promoter by bisulfite sequencing of multiple clones.
Results: Although there was a difference between the methylation level of the two alleles in some
samples, there was no mono-allelic promoter hypermethylation in any of the samples.
Conclusion: These results suggest that germline mono-allelic hypermethylation of the CDH1
promoter is not a major predisposing factor for gastric cancer.
Background
Gastric cancer is one of the most common cancers world-
wide, including in Japan, and gastric carcinogenesis is a
multistep process in which environmental and genetic
factors interact [1-6]. Among the genetic factors, the
CDH1  gene, alternatively referred to as the E-cadherin
gene, is one of the most important tumor suppressor
genes in gastric cancer [6], and mutations, chromosomal
deletions, and epigenetic modifications have been
reported as mechanisms that cause CDH1 inactivation [6-
17]. Somatic CDH1 mutations have been found in about
50% of diffuse-type gastric cancers [7], and germline
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CDH1 mutations have been reported in familial gastric
cancers in several ethnic groups [6,8-13]. Promoter region
hypermethylation, histone deacetylation, and chromatin
condensation have been reported as epigenetic events in
the CDH1 gene [14-17]. Among these mechanisms that
cause CDH1 inactivation, inactivating germline muta-
tions are the only genetic mechanism which is inherited
in gastric cancer. Furthermore, since the germline CDH1
mutations have been found in only a certain percentage of
familial gastric cancers, it is reasonable to hypothesize
that CDH1 inactivation due to a previously unknown
mechanism or inactivation of another gene plays a role in
predisposing to gastric cancer. Interestingly, a germline
mono-allelic hypermethylation of the MLH1  or  MSH2
promoter has recently been reported in a subset of fami-
lies with hereditary nonpolyposis colorectal cancer
(HNPCC) [18-21]. Although mutations or chromosomal
deletions in MLH1 and MSH2 have long been known to
be hereditary genetic factors in HNPCC patients [22], such
a germline epigenetic modification is a novel mechanism
for the disease. Based on all of the above, we hypothesized
that germline mono-allelic hypermethylation of the
CDH1 promoter is responsible for gastric cancer, and in
the present study we tested this hypothesis by examining
the lesions of 39 patients with familial gastric cancer or
early-onset gastric cancer. Furthermore, since germline
CDH1  mutations are rarely found in gastric cancer
patients with no family history of gastric cancer [23,24],
we considered it worth examining patients with sporadic
gastric cancer, even though the possibility of detecting
germline mono-allelic hypermethylation of the CDH1
promoter may be small in that group.
Methods
Tissue samples, cell lines, and nucleic acid extraction
Although the diagnostic criteria for hereditary diffuse gas-
tric cancer have been defined by the International Gastric
Cancer Linkage Consortium [9], the Consortium also
noted that the criteria should not be applied in Japan and
Korea, where the background incidence of gastric cancer is
high. In the present study we tentatively used the criterion
"a proband and one or more cases of gastric cancer in the
first-degree relatives" and called the cases collected famil-
ial gastric cancer. In this study "early-onset gastric cancer"
is defined as gastric cancer diagnosed before 50 years of
age. Blood samples were collected from 39 patients with
familial gastric cancer or early-onset gastric cancer
[12,25], and all of whom had been shown to be negative
for germline CDH1  mutations [12,25]. Non-cancerous
gastric tissue was collected from 159 gastric cancer
patients treated at the Hamamatsu University Hospital.
HeLa, HL-60, H358, and HT-29 cell lines were purchased
from the American Type Culture Collection (Manassas,
VA), and Lu-135 and MKN74 cell lines were purchased
from Human Science Research Resource Bank (Osaka,
Japan). Genomic DNA was extracted with a QIAamp DNA
Blood Maxi Kit (QIAGEN, Valencia, CA) or with a DNeasy
Tissue Kit (QIAGEN). Total RNA was extracted with an
RNeasy Mini Kit (QIAGEN). The research protocol was
approved by the Institutional Review Board of Hama-
matsu University School of Medicine.
Reverse transcription (RT)-polymerase chain reaction 
(PCR) analysis
Total RNA was converted to cDNA by using the Super-
Script First-Strand Synthesis System for RT-PCR (Invitro-
gen, Carlsbad, CA) according to the manufacturer's
instructions. PCR amplification was performed using the
following sets of primers: 5'-AGA ACG CAT TGC CAC ATA
CAC-3' and 5'-GAG GAT GGT GTA AGC GAT GG-3' for
the CDH1 transcripts and 5'-CCA AGG TCA TCC ATG
ACA AC-3' and 5'-CAC CCT GTT GCT GTA GCC A-3' for
the GAPDH transcripts. PCR products were fractionated
by electrophoresis on a 2.0% agarose gel and stained with
ethidium bromide, and the gel was examined under UV
light. A 100-bp DNA ladder (New England Biolabs, Bev-
erly, MA) was used.
Genotyping analysis
The -348_-347insA, -161C>A, and -73A>C polymor-
phisms in the CDH1 promoter region were genotyped by
PCR-restriction fragment length polymorphism (RFLP)
analysis. These polymorphisms are denoted based on the
GenBank accession number NT_010498 (CDH1 reference
sequence used in this study). The -161C>A polymorphism
has also been reported as the -160C>A polymorphism in
several previous papers [26]. The CDH1 promoter region
was amplified by PCR with HotStarTaq DNA polymerase
(QIAGEN) and the following set of primers: 5'-GCT ACT
AGA GAG GCT GGG GC-3' and 5'-TCA CAG GTG CTT
TGC AGT TC-3'. The PCR products were digested with
BsmAI for the -348_-347insA polymorphism and with
BstEII for the -161C>A and -73A>C polymorphisms. The
digestion products were separated by electrophoresis on a
2.0% agarose gel and stained with ethidium bromide, and
the gel was examined under UV light. To validate the
results of the PCR-RFLP analysis, some PCR products
exhibiting a different genotype in the PCR-RFLP analysis
were randomly selected and directly sequenced with a
BigDye Terminator Cycle Sequencing Reaction Kit
(Applied Biosystems, Tokyo, Japan) and an ABI 3100
Genetic Analyzer (Applied Biosystems). Deviation of gen-
otype distribution from the Hardy-Weinberg equilibrium
(HWE) was tested with SNPAlyze software (Dynacom,
Yokohama, Japan).
Immunohistochemical analysis
Paraffin-embedded tissue sections were deparaffinized,
rehydrated, and antigen-retrieved. The sections were then
treated with 3% hydrogen peroxide to block endogenous
peroxidase activity. Next, the sections were incubated with
an anti-CDH1 monoclonal antibody (clone 36B5; Novo-Molecular Cancer 2009, 8:63 http://www.molecular-cancer.com/content/8/1/63
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castra, Newcastle, UK), and then with dextran polymer
conjugated with goat anti-mouse IgG and horseradish
peroxidase (ChemMate Envision Kit, DAKO, Kyoto,
Japan). The antigen-antibody complex was visualized
with 3,3'-diaminobenzidine tetrahydrochloride and
counterstained with hematoxylin. This analysis was per-
formed with a DAKO autostainer (DAKO) [27]. Hematox-
ylin-eosin (H-E) stained slides were also prepared.
Allele-specific methylation analysis
A 500 ng sample of genomic DNA was treated with
sodium bisulfite using the EpiTect Bisulfite Kit (QIAGEN)
according to the manufacturer's instructions. The CDH1
promoter region was amplified by PCR with HotStarTaq
DNA polymerase (QIAGEN) and the bisulfite-treated
DNA. The primers used were 5'-TTT TTT TTG ATT TTA
GGT TTT AGT GAG-3' and 5'-ACT CCA AAA ACC CAT
AAC TAA CC-3' for DNA extracted from the cell lines and
5'-TGG TGG TGT GTA TTT GTA TTT TTA GGA G-3' and 5'-
ACT CCA AAA ACC CAT AAC TAA CC-3' for DNA
extracted from blood or gastric tissue. The PCR conditions
consisted of initial denaturation at 95°C for 15 min, 45
cycles of denaturation at 94°C for 30 sec, annealing at
59°C for 30 sec, and extension at 72°C for 1 min, and
then a final extension at 72°C for 10 min. The PCR prod-
uct was subcloned into a pGEM-T Easy vector (Promega,
Madison, WI). At least 8 clones were sequenced with a
BigDye Terminator Cycle Sequencing Reaction Kit
(Applied Biosystems) and an ABI 3100 Genetic Analyzer
(Applied Biosystems). The sequencing results and geno-
typing results for the -348_-347insA, -161C>A, or -73A>C
polymorphisms described in "Genotyping analysis" sec-
tion were used to evaluate allele-specific methylation sta-
tus in the analysis of blood and gastric tissue.
Results
Inverse association between CDH1 promoter methylation 
level and CDH1 mRNA expression level in human cell lines
First, we tried setting up an experimental system that
could be used to evaluate the methylation status of the
CDH1 promoter in human cells. Six human cell lines, Lu-
135, HeLa, HL-60, H358, HT-29, and MKN74, were exam-
ined for mRNA expression by RT-PCR analysis, and the
results showed no CDH1 expression in the Lu-135, HeLa,
and HL-60 cells but strong CDH1 expression in the H358,
HT-29, and MKN74 cells (Figure 1A). The status of CDH1
expression in the HeLa, HL-60, and HT-29 cells was com-
patible with previous reports [28,29], and the results in
the other cell lines were novel findings. Next, the methyl-
ation status of 33 CpG sites in the CDH1 promoter region
was examined in the six cell lines by bisulfite sequencing
(Figure 1B). The results showed that the CpG sites in the
CDH1 promoter were thoroughly methylated in the Lu-
135, HeLa, and HL-60 cell lines, which did not express
CDH1, but that they were almost completely unmethyl-
ated in the H358, HT-29, and MKN74 cell lines, which
expressed CDH1 (Figure 1C). These results indicated that
the  CDH1  promoter methylation status of human cell
lines as determined by our bisulfite sequencing analysis is
inversely associated with the mRNA expression status of
the CDH1 gene. They also indicated that the experimental
system we set up to evaluate the methylation status of the
CDH1 promoter was valid.
Absence of germline mono-allelic hypermethylation in the 
CDH1 promoter in gastric cancer
We tried investigating the allele-specific methylation sta-
tus of the CDH1 promoter in two groups of gastric can-
cers, a familial gastric cancer or early-onset gastric cancer
group and a sporadic gastric cancer group. Since informa-
tion on the genetic polymorphisms within the CDH1 pro-
moter region is useful for discriminating the CDH1 alleles
subcloned in the bisulfite sequencing analysis, the -348_-
347insA, -161C>A, and -73A>C polymorphisms in the
CDH1  promoter region were genotyped by PCR-RFLP
analysis (Table 1). All the genotyping results were in HWE
(P > 0.05). The DNA in the blood of 39 patients with
familial gastric cancer or early-onset gastric cancer was
genotyped and the 22 patients with at least one hetero-
zygous promoter polymorphism were selected. Loss of
CDH1 protein expression identified by CDH1 immuno-
histochemical analysis, in addition to selection by poly-
morphism genotyping, was used to select the sporadic
group (Figure 2). As a result, 18 patients with sporadic
gastric cancer showing loss of CDH1 protein expression
were ultimately chosen from a total of 159 patients. We
then tested DNA from the blood of the 22 patients with
familial gastric cancer or early-onset gastric cancer and
DNA from non-cancerous gastric tissue of the 18 patients
with sporadic gastric cancer to determine the methylation
status of the CDH1 promoter region by bisulfite sequenc-
ing analysis. Various percentages of methylation of CpG
sites in the CDH1 promoter were detected, but the nearly
complete methylation of the sites observed in the analysis
of the cell lines was not found in any of the samples (Fig-
ure 3 and 4). Interestingly, there were differences between
the methylation level of the two CDH1 alleles in some
non-cancerous gastric tissue samples (e.g., S12 and S14 in
Figure 4), but the clear mono-allelic hypermethylation
observed in the MLH1 promoter of the HNPCC patients
[18-20] was not observed in the CDH1 promoter in any of
the samples (Figure 3 and 4). These results suggest that
germline mono-allelic hypermethylation of the CDH1
promoter is not a major predisposing factor for gastric
cancer.
Discussion
In this study blood from 22 patients with familial gastric
cancer or early-onset gastric cancer and non-cancerous
gastric tissues from 18 patients with sporadic gastric can-Molecular Cancer 2009, 8:63 http://www.molecular-cancer.com/content/8/1/63
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Inverse association between CDH1 promoter methylation level and CDH1 mRNA expression level in human cell lines Figure 1
Inverse association between CDH1 promoter methylation level and CDH1 mRNA expression level in human 
cell lines. (A) Detection of the CDH1 mRNA transcripts in 6 human cell lines by reverse transcription (RT)-polymerase chain 
reaction (PCR) analysis. mRNA transcripts of the GAPDH, a housekeeping gene, were also amplified as an internal control. M, 
100-bp DNA ladder. (B) Map of the CpG sites in the CDH1 promoter. The positions of the CpG sites are indicated by vertical 
lines. Vertical arrows indicate the location of the -348_-347insA, -161C>A, and -73A>C genetic polymorphisms. +1, transcrip-
tion start site. (C) Determination of the methylation status of the CpG sites in the CDH1 promoter in 6 human cell lines by 
bisulfite sequencing analysis. Ten subcloned promoter fragments were sequenced in each cell line. Each horizontal row repre-
sents a single allele. The positions of the CpG sites are numbered at the top of the column. Methylated CpG sites are shown as 
black boxes and unmethylated CpG sites as white boxes.
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cer showing loss of CDH1 expression was analyzed for
allele-specific methylation status of the CDH1 promoter
by bisulfite sequencing analysis. Although a difference
between the methylation level of the two CDH1 alleles
was found in some non-cancerous gastric tissue samples,
no mono-allelic promoter hypermethylation of the CDH1
gene was detected in any of them. This finding suggests
that germline promoter hypermethylation of the CDH1
gene is not involved in any mechanism that causes suscep-
tibility to gastric cancer. This is the first report of an inves-
tigation into whether germline mono-allelic
hypermethylation of the CDH1 promoter is a predispos-
ing factor for gastric cancer.
Since bisulfite allelic sequencing enables detailed, base-
by-base measurement of CpG methylation and discrimi-
nation between the wild-type and variant type at the pol-
ymorphism site, we used it to determine methylation
status in the CDH1 promoter region. The results showed
that CDH1 promoter methylation status determined by
the bisulfite sequencing analysis was inversely associated
with mRNA expression status of the CDH1 gene in the
human cell lines, indicating that a valid system had been
established. However, no mono-allelic hypermethylation
of the CDH1 promoter was found in any of the samples,
suggesting that it is not a predisposing factor for gastric
cancer. Caution is required, however, since the absence of
germline mono-allelic promoter hypermethylation in this
study may have been due to the limited number of
patients analyzed and Hitchins et al. reported a very low
incidence of germline mono-allelic hypermethylation of
the MLH1 promoter in HNPCC (1 out of 160 HNPCC
candidates) [19], it is impossible to rule out the possibility
that analysis of a larger number of gastric cancer patients
would reveal cases with germline mono-allelic hyper-
methylation of the CDH1 promoter. However, there were
two reasons for the limited number of patients utilized for
the allele-specific methylation analysis in our study. One
reason is that the incidence of familial gastric cancer or
early-onset gastric cancer is relatively low, and the other is
that selection in regard to CDH1  promoter polymor-
phisms and CDH1 expression was necessary in this study.
We therefore think that the results of our investigation of
these selected samples are very important. Since all of the
patients with familial gastric cancer or early-onset gastric
cancer whose samples we analyzed had already been
shown to be negative for germline CDH1  mutation
[12,25], genetic or epigenetic events in other genes may
Table 1: Distribution of the genotypes of the three CDH1 promoter polymorphisms in gastric cancer patients
Genetic polymorphisma dbSNP IDb Samplesc Number of patients with a 
heterozygous genotype (%)
Number of patients homozygous 
for a varinat allele (%)
Variant allele frequency
-348_-347insA rs5030625 F/EGC 9 (23.1%) 4 (10.3%) 21.8%
SGC 55 (34.6%) 15 (9.4%) 26.7%
-161C>A rs16260 F/EGC 11 (28.2%) 0 (0.0%) 14.1%
SGC 51 (32.1%) 7 (4.4%) 20.4%
-73A>C rs28372783 F/EGC 5 (12.8%) 0 (0.0%) 6.4%
SGC 19 (11.9%) 0 (0.0%) 6.0%
a Nucleotide +1 is the transcription start site. The reference sequence is accession number NT_010498.
b Identification number registered in the database of single nucleotide polymorphisms (dbSNP) homepage of the National Center for Biotechnology 
Information web site http://www.ncbi.nlm.nih.gov/SNP/.
c F/EGC, familial gastric cancer or early-onset gastric cancer; SGC, sporadic gastric cancer.
Immunohistochemical examination of CDH1 protein expres- sion in sporadic gastric cancers Figure 2
Immunohistochemical examination of CDH1 protein 
expression in sporadic gastric cancers. Representative 
gastric cancer samples are shown. (A) and (C), sporadic gas-
tric cancer showing CDH1 protein expression; (B) and (D), 
sporadic gastric cancer not showing CDH1 expression. (A) 
and (B), H-E stained; (C) and (D), immunostained for CDH1. 
Scale bar, 50 μm.
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DNA methylation patterns of the CDH1 promoter in the blood of patients with familial gastric cancer or early-onset gastric  cancer determined by bisulfite sequencing analysis Figure 3
DNA methylation patterns of the CDH1 promoter in the blood of patients with familial gastric cancer or early-
onset gastric cancer determined by bisulfite sequencing analysis. Eight subcloned promoter fragments were 
sequenced in each sample, and the results for 14 representative samples are shown. Each horizontal row represents a single 
allele. The positions of the CpG sites are numbered at the top of the column. Methylated CpG sites are shown as black boxes, 
and unmethylated CpG sites as white boxes. The far right column indicates the allele of the -348_-347insA, -161C>A, or -
73A>C polymorphism: wild-type allele, red; variant-type allele, sky blue.
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DNA methylation patterns of the CDH1 promoter in non-cancerous gastric tissue from patients with sporadic gastric cancer  determined by bisulfite sequencing analysis Figure 4
DNA methylation patterns of the CDH1 promoter in non-cancerous gastric tissue from patients with sporadic 
gastric cancer determined by bisulfite sequencing analysis. At least 8 subcloned promoter fragments were sequenced 
in each sample, and the results for 15 representative samples are shown. Each horizontal row represents a single allele. The 
positions of the CpG sites are numbered at the top of the column. Methylated CpG sites are shown as black boxes, and 
unmethylated CpG sites as white boxes. The far right column indicates the allele of the -348_-347insA, -161C>A, or -73A>C 
polymorphism: wild-type allele, red; variant-type allele, sky blue.
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have been involved in the gastric carcinogenesis in those
patients.
Although no mono-allelic hypermethylation of the CDH1
promoter was detected in this study, various levels of
methylation of CpG sites in the CDH1  promoter were
detected in all of the samples. This finding is compatible
with findings reported previously [30,31] and may be
related to aging or Helicobacter pylori infection as reported
in those papers [30,31]. Interestingly, there were differ-
ences between the two alleles in methylation level of the
CDH1  promoter in some non-cancerous gastric tissue
samples. Allele-specific methylation of the CDH1  pro-
moter has been reported to be the second genetic hit in
gastric cancer tissue from patients with familial gastric
cancer [15], but the mechanism underlying the CDH1
allele-specific methylation has not been elucidated in
either non-cancerous or cancerous gastric tissue. Future
investigation of this point should improve our under-
standing of gastric carcinogenesis.
Since germline mono-allelic promoter hypermethylation
and transgenerational inheritance of such an epigenetic
event is a recent finding in humans, there have been only
a small number of papers documenting the germline epi-
genetic modification. Heritable germline mono-allelic
hypermethylation of the MLH1 or MSH2 gene has been
found in a subset of families with HNPCC [18-21]. On the
other hand, similar investigation of the APC  gene in
patients with familial adenomatous polyposis (FAP),
attenuated FAP, and hyperplastic polyposis, of the BRCA1
gene in patients with familial breast cancer, and of the
CDKN2A gene in patients with familial melanoma have
revealed no germline mono-allelic promoter hypermeth-
ylation of any of these genes [32-34]. Based on these find-
ings and the results of our own study, germline mono-
allelic hypermethylation is unlikely to be present in all
genes responsible for hereditary cancer syndromes. Thus,
it will be important to identify genes with germline epige-
netic modifications in the future, because the results will
be useful in making a precise diagnosis and in conducting
surveillance and management of cancer patients and their
family members.
In this study the distribution of the genotypes of the three
CDH1 promoter polymorphisms was in HWE, and the
results of PCR-RFLP analysis were confirmed by direct
sequencing in some samples. This means our genotyping
was performed properly, and proper genotyping was
important to selecting the gastric cancer patients in our
study. Since there is a CDH1 haplotype associated with
increased gastric cancer risk and the haplotype contains
the -161A allele [3], the genotyping method will be also
valuable for evaluating the risk of gastric cancer.
There are two main histopathological types of gastric can-
cer, a diffuse-type and an intestinal-type. The 5-year sur-
vival rate has been reported to be lower for diffuse-type
gastric cancer than for intestinal-type gastric cancer, and
the incidence of peritoneal recurrence has been reported
to be higher in diffuse-type gastric cancer than in intesti-
nal-type gastric cancer [35,36]. Although no germline
mono-allelic hypermethylation of the CDH1  promoter
was found in this study, we believe it is important to con-
tinue to evaluate CDH1 gene status from various stand-
points, because CDH1 inactivation is closely related to the
pathogenesis of diffuse-type gastric cancer.
Conclusion
The present results suggest that germline mono-allelic
hypermethylation of the CDH1 promoter is not a major
predisposing factor for gastric cancer.
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